CheckMate-648 focused exclusively on ESCC patients and introduced the use of nivolumab (an anti-PD-1 antibody) combined with FP chemotherapy, with or without ipilimumab (an anti-CTLA-4 antibody). Here, PDCD1 is linked to esophageal squamous cell carcinoma.